Anti Malaria Campaign, Colombo, Sri Lanka.
Regional Malaria Office, Moneragala, Sri Lanka.
Malar J. 2020 Sep 25;19(1):346. doi: 10.1186/s12936-020-03419-x.
Following malaria elimination, Sri Lanka was free from indigenous transmission for six consecutive years, until the first introduced case was reported in December 2018. The source of transmission (index case) was a member of a group of 32 migrant workers from India and the location of transmission was their residence reporting a high prevalence of the primary vector for malaria. Despite extensive vector control the situation was highly susceptible to onward transmission if another of the group developed malaria. Therefore, Mass Radical Treatment (MRT) of the group of workers for Plasmodium vivax malaria was undertaken to mitigate this risk.
The workers were screened for malaria by microscopy and RDT, their haemoglobin level assessed, and tested for Glucose 6 phosphate dehydrogenase deficiency (G6PD) using the Care Start RDT and Brewers test prior to treatment with chloroquine (CQ) 25 mg/kg body weight (over three days) and primaquine (PQ) (0.25 mg/kg/day bodyweight for 14 days) following informed consent. All were monitored for adverse events.
None of the foreign workers were parasitaemic at baseline screening and their haemoglobin levels ranged from 9.7-14.7 g/dl. All 31 individuals (excluding the index case treated previously) were treated with the recommended dose of CQ. The G6PD test results were inconclusive in 45% of the RDT results and were discrepant between the two tests in 31% of the remaining test events. Seven workers who tested G6PD deficient in either test were excluded from PQ and the rest, 24 workers, received PQ. No serious adverse events occurred.
Mass treatment may be an option in prevention of reintroduction settings for groups of migrants who are likely to be carrying latent malaria infections, and resident in areas of high receptivity. However, in the case of Plasmodium vivax and Plasmodium ovale, a more reliable and affordable point-of-care test for G6PD activity would be required. Most countries which are eliminating malaria now are in the tropical zone and face considerable and similar risks of malaria re-introduction due to massive labour migration between them and neighbouring countries. Regional elimination of malaria should be the focus of global strategy if malaria elimination from countries is to be worthwhile and sustainable.
斯里兰卡在消除疟疾后连续六年没有本地传播,直到 2018 年 12 月报告首例输入病例。传播源(输入病例)是来自印度的 32 名移民工人中的一员,传播地点是他们居住的地方,那里疟疾病媒的流行率很高。尽管进行了广泛的病媒控制,但如果该群体中的另一个人感染疟疾,情况仍极易继续传播。因此,对该批工人进行了大规模根治性治疗(MRT),以治疗间日疟原虫疟疾,以降低这种风险。
通过显微镜和快速诊断检测(RDT)筛查工人的疟疾情况,评估其血红蛋白水平,并在氯喹(CQ)25mg/kg 体重(分三天服用)和伯氨喹(PQ)(0.25mg/kg/天体重,服用 14 天)治疗前,使用 Care Start RDT 和 Brewers 试验检测葡萄糖-6-磷酸脱氢酶缺乏症(G6PD)。所有工人均进行不良事件监测。
没有外来工人在基线筛查时出现寄生虫血症,其血红蛋白水平在 9.7-14.7g/dl 之间。所有 31 名个体(除了之前接受治疗的输入病例)均按推荐剂量服用 CQ。在 45%的 RDT 结果中,G6PD 检测结果不确定,在其余 31%的检测事件中,两种检测结果不一致。在这两种检测中,有 7 名 G6PD 缺乏的工人被排除在 PQ 治疗之外,其余 24 名工人接受了 PQ 治疗。没有发生严重不良事件。
对于可能携带潜伏性疟原虫感染且居住在高易感性地区的移民群体,大规模治疗可能是预防重新引入的一种选择。然而,对于间日疟原虫和卵形疟原虫,需要更可靠和负担得起的即时检测点,以检测 G6PD 活性。目前正在消除疟疾的大多数国家都在热带地区,由于它们与邻国之间大量的劳动力迁移,面临着相当大的、类似的疟疾重新输入的风险。如果要使国家消除疟疾有价值并可持续,就应该把区域消除疟疾作为全球战略的重点。